Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a treatment called betaine hydrochloride for people with autoimmune gastritis (AIG), a condition that damages the stomach lining and can lead to problems like low vitamin absorption and an increased risk of certain stomach cancers. The goal is to see if betaine hydrochloride can help improve stomach symptoms, restore normal levels of a hormone called gastrin, and reduce the risk of complications like tumors or cancer by creating a healthier acidic environment in the stomach.

To be eligible for this trial, participants should be between 18 and 80 years old, have a confirmed diagnosis of autoimmune gastritis, and have high levels of gastrin or a history of certain stomach tumors. However, those with allergies to betaine hydrochloride or other specific stomach conditions will not be able to participate. If someone joins the study, they can expect to undergo evaluations related to their stomach health and may receive betaine hydrochloride as part of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with autoimmune gastritis at the Second Affiliated Hospital of Zhejiang University School of Medicine, with the diagnostic criteria for autoimmune gastritis based on the article "A real-world study on the characteristics of autoimmune gastritis: A single-center retrospective cohort in China" published by our team in the journal Clinics and Research in Hepatology and Gastroenterology;
• • 2. Gastrin levels greater than 300 pmol/L or a history of type 1 gastric neuroendocrine tumors or early gastric cancer treated with endoscopic submucosal dissection (ESD);
• • 3. Age between 18 and 80 years;
• • 4. Patients who have signed the informed consent form for the clinical trial.
• Exclusion Criteria:
• • 1. Patients allergic to betaine hydrochloride;
• • 2. Patients with peptic ulcers;
• • 3. Patients with any condition other than autoimmune gastritis that causes elevated gastrin levels (e.g., gastrinoma);
• • 4. Patients who refuse to sign the informed consent form.